Lynx1 Capital Management LP T Scan Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $257 Million
- Q4 2024
A detailed history of Lynx1 Capital Management LP transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 5,357,347 shares of TCRX stock, worth $11.3 Million. This represents 6.28% of its overall portfolio holdings.
Number of Shares
5,357,347
Previous 5,224,600
2.54%
Holding current value
$11.3 Million
Previous $26 Million
37.82%
% of portfolio
6.28%
Previous 9.31%
Shares
4 transactions
Others Institutions Holding TCRX
# of Institutions
89Shares Held
41.1MCall Options Held
0Put Options Held
0-
Eco R1 Capital, LLC San Francisco, CA5MShares$10.5 Million0.71% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$9.37 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$7.35 Million0.02% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$6.28 Million0.34% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$5.85 Million0.09% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $39.8M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...